Skip to content

Startup & venture capital news

Alethio raises USD 90m for blood cancer therapies

Sofinnova, RA Capital and Oxford Science Enterprises co lead the Series A

By /

LinkedInX
Alethio Therapeutics: Alethio raises USD 90m for blood cancer therapies

Alethio Therapeutics announced an oversubscribed USD 90 million Series A to advance treatments for myeloproliferative neoplasms. Sofinnova Partners and RA Capital co led the round alongside founding investor Oxford Science Enterprises, with Cancer Research Horizons and the University of Oxford also participating. The Oxford biotechnology company is developing ATX 011, a therapy intended to reduce disease driving cells in essential thrombocythaemia. Chief executive Rohit Batta plans to use the financing for Phase 1 and Phase 2a studies and additional programmes. The candidate remains preclinical, so its proposed mechanism and therapeutic potential are not evidence of safety or efficacy in patients.

Keep reading

More Funding

All stories